![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
COCRYSTAL: A NOVEL APPROACH FOR BIOAVAILABILITY ENHANCEMENT
Sagar Jasud*, Shubhangi Warad, Solunke Rahul, Ganesh Jagdale, Shilpa Zinjad
ABSTRACT Co-crystallization alters the molecular interactions and composition of pharmaceutical materials, and is considered better alternatives to optimize drug properties. Crystal form is crucial to the performance of dosage form. The use of co-crystal technology in active pharmaceutical ingredient (API) crystallizations is as an enabling technology to bring improved pharmaceutical products to the marketplace as well as for improved drug delivery Pharmaceutical co-crystals represent a hopeful class of pharmaceutical materials offering the prospect of better alternatives to optimize drug physical properties and biopharmaceutical issues such as solubility, stability and bioavailability in pharmaceutical development without changing the chemical composition of the API, thereby, giving new patentable solid forms. Various applications of pharmaceutical co-crystals also include chiral resolution. Dissociation of the API from its excipient in co-crystals prior to reaching the site of action is desirable for pharmacological activity. The crystalline solid forms with improved physical properties may impact the pharmaceutical intellectual property landscape. Keywords: Cocrystal, Solubility and Bioavailability Aspects, Drug Solubility, Novel [Download Article] [Download Certifiate] |